StockData
Inhibrx Biosciences, Inc. logo

Inhibrx Biosciences, Inc. (INBX) stock

INBXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 13, 2026Score 1/30
$74.18−3.48 (-4.48%)

Close on Nov 17, 2026Market cap $1.09BP/E –Yield –

Inhibrx Biosciences r&d expenses

Research and development expenses are spending on new products and technology.

Inhibrx Biosciences's R&D Expenses for the twelve months ending Sep 30, 2026 was $100.43M, down 17.0% year over year. For fiscal 2025 it was $113.03M, down 44.5% from the year before. The highest annual figure on record is $203.74M in fiscal 2024.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$113.03M-44.5%
FY2024Dec 31, 2024$203.74M+6.3%
FY2023Dec 31, 2023$191.64M+73.9%
FY2022Dec 31, 2022$110.19M+54.2%
FY2021Dec 31, 2021$71.44M-2.8%
FY2020Dec 31, 2020$73.50M+53.4%
FY2019Dec 31, 2019$47.91M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$25.97M-9.0%
Q2 FY2026Jun 30, 2026$23.90M+7.3%
Q1 FY2026Mar 31, 2026$25.22M-31.6%
Q4 FY2025Dec 31, 2025$25.35M-24.0%
Q3 FY2025Sep 30, 2025$28.54M-26.6%
Q2 FY2025Jun 30, 2025$22.27M-67.1%
Q1 FY2025Mar 31, 2025$36.88M-42.2%
Q4 FY2024Dec 31, 2024$33.37M-59.4%
Q3 FY2024Sep 30, 2024$38.89M+2.2%
Q2 FY2024Jun 30, 2024$67.63M+98.3%
Q1 FY2024Mar 31, 2024$63.85M+70.8%
Q4 FY2023Dec 31, 2023$82.09M+169.6%
Q3 FY2023Sep 30, 2023$38.06M+52.6%
Q2 FY2023Jun 30, 2023$34.11M+14.0%
Q1 FY2023Mar 31, 2023$37.39M+50.2%
Q4 FY2022Dec 31, 2022$30.45M+63.6%
Q3 FY2022Sep 30, 2022$24.93M+34.9%
Q2 FY2022Jun 30, 2022$29.91M+67.1%
Q1 FY2022Mar 31, 2022$24.90M+51.4%
Q4 FY2021Dec 31, 2021$18.62M+5.4%
Q3 FY2021Sep 30, 2021$18.49M-6.8%
Q2 FY2021Jun 30, 2021$17.90M-5.6%
Q1 FY2021Mar 31, 2021$16.44M-3.4%
Q4 FY2020Dec 31, 2020$17.67M+43.8%
Q3 FY2020Sep 30, 2020$19.84M+55.2%
Q2 FY2020Jun 30, 2020$18.97M–
Q1 FY2020Mar 31, 2020$17.02M–
Q4 FY2019Dec 31, 2019$12.28M–
Q3 FY2019Sep 30, 2019$12.79M–

More Inhibrx Biosciences figures

See a number that looks wrong?